The AI-powered genetic-testing company has been a strong performer. The CEO's recent move had more to do with accounting than conviction.Katherine Stueland, CEO of GeneDx Holdings Corp. (WGS +0.53%), executed an open-market sale of 2,158 shares on October 29, 2025, following an option exercise as disclosed in this SEC Form 4 filing.Transaction summaryMetricValueShares sold2,158Transaction value~$294,654Post-transaction shares3,436Post-transaction value (direct ownership)~$470,000Transaction value calculated ...